Hao-Fountain Syndrome: 32 novel patients reveal new insights into the clinical spectrum

Updating the clinical spectrum of HAFOUS

Moritz Claudius Wimmer[1] (moritz.wimmer@med.uni-heidelberg.de),
Laura Dötsch[1] (laura.doetsch@med.uni-heidelberg.de),
Samy Unser[1] (samy.unser@med.uni-heidelberg.de),
Heiko Brennenstuhl[1] (heiko.brennenstuhl@med.uni-heidelberg.de),
Pilar Caro[1] (MariadelPilar.CaroMartin@med.uni-heidelberg.de),
Christian Patrick Schaaf[1,2] (christian.schaaf@med.uni-heidelberg.de)

[1]Institute of Human Genetics, Heidelberg University, Heidelberg
[2]Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA

Correspondence:
Christian Patrick Schaaf, Institute of Human Genetics, University of Heidelberg, Im Neuenheimer Feld 366, D-69120 Heidelberg, Germany
christian.schaaf@med.uni-heidelberg.de

Ethical statement:
This study was performed under the research protocol H-34578, approved by the Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals. All individuals and their guardians were informed and provided consent for the study.

Statement of contribution:
Methodology: MCW, SU, HB; Data curation: MCW, LD, PC; Project administration: MCW, PC; Writing – original draft: MCW; Writing – review and editing: CPS, MCW; Supervising: CPS

Acknowledgments:
The authors thank the individuals and the families with Hao-Fountain syndrome, who have provided clinical data and overwhelming support for our efforts. The authors also thank Ferdinand Althammer and Jannis Bücking for comments that greatly improved the manuscript.

Conflicts of interest:
The authors declare no competing interests.

Data Availability statement:
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

Abstract

Hao-Fountain syndrome (HAFOUS, OMIM: #616863) is a neurodevelopmental disorder caused by pathogenic variants in the gene *USP7* coding for USP7, a protein involved in several crucial cellular homeostatic mechanisms and the recently described MUST complex. The phenotype of HAFOUS is insufficiently understood, yet there is a great need to better understand the spectrum of disease, genotype-phenotype correlations, and disease trajectories.

We now present a larger cohort of 32 additional individuals and provide further clinical information about six previously reported individuals. A questionnaire-based study was performed to characterize the phenotype of Hao-Fountain syndrome more clearly, to highlight new traits, and to better distinguish the disease from related neurodevelopmental disorders. In addition to confirming previously described features, we report hyperphagia and increased body weight in a subset of individuals. HAFOUS patients present an increased rate of birth complications, congenital anomalies, and abnormal pain thresholds. Speech impairment emerges as a potential hallmark of Hao-Fountain syndrome. Cognitive testing reports reveal borderline intellectual functioning on average, although some individuals score in the range of intellectual disability.

Finally, we created a syndrome-specific severity score. This score neither indicates a sex- nor age-specific difference of clinical severity, yet highlights a more severe outcome when amino acid changes colocalize to the catalytic domain of the USP7 protein.

Keywords

USP7, Hao-Fountain syndrome, neurodevelopmental disorder, rare disease, clinical spectrum, genotype-phenotype association

Introduction

Ubiquitin-specific protease 7 (USP7), also known as Herpesvirus-associated protease (HAUSP), plays a crucial role as a regulator of ubiquitination in genome stability pathways[1]. There is correlation between USP7 deviance and cancer progression, initially described as having a tumor suppressive role and more recently in addition with context-dependent oncogenic functions[2]. USP7 serves to maintain genome integrity functions via cell cycle regulation, DNA replication, telomere regulation, DNA repair, epigenetic mechanisms, and apoptosis[1,3].

USP7 harbors dual function, as it deubiquitinates both an E3 ubiquitin ligase and the substrates targeted by such[1,4]. This dichotomy was also demonstrated in the MUST pathway, a multiprotein pathway regulating WASH activity, an actin nucleation-promoting factor activated by ubiquitination, closely involved in intracellular protein trafficking and recycling[5]. USP7 was shown to deactivate WASH by deubiquitination while also protecting the corresponding E3 Ligase (TRIM27) from degradation and therefore promoting WASH ubiquitination[6]. Another protein involved in this pathway, MAGEL2, is associated with Schaaf-Yang (SYS, OMIM #615547)[7] and Prader-Willi syndromes (PWS, OMIM #176270)[8], and USP7

haploinsufficiency was subsequently shown to also cause a neurodevelopmental disorder[6,9]. The initial report included seven individuals, six cases with genomic deletions containing the *USP7* gene and one individual with a *USP7* nonsense mutation[6]. Patients presented with developmental delay (DD), autism spectrum disorder (ASD), seizures, a behavioral phenotype, and signs of hypogonadism. Intriguingly, this clinical presentation shows great overlap with two other *MAGEL2*-associated disorders[10].

The clinical spectrum of SYS, caused by truncating mutations within *MAGEL2*, overlaps with *USP7*-related disorder and PWS by neurodevelopmental delay, failure to thrive, and endocrine disruptions but remains distinct by its high prevalence of ASD and its more severe phenotype concerning intellectual functioning and lethality[11-13].

To date, the largest cohort of patients affected by Hao-Fountain Syndrome (HAFOUS, OMIM: #616863) was presented by Fountain et al. in 2019 describing 16 novel patients[9]. The consistency of symptoms, regardless of the underlying variant type, supported the concept of USP7 haploinsufficiency as the causal factor of the disorder. Individuals presented with DD/ID, eye anomalies, feeding difficulties, GERD, behavioral anomalies, and ASD as the most frequent features. Furthermore, an in-depth secondary analysis of brain MRI images revealed various morphological anomalies with white matter paucity as the most frequent finding, reflected by a significant reduction of thickness of both splenium and body of the corpus callosum[9].

In subsequent case reports, six more patients were added to the publicly available cohort[14-17]. These new cases implicate a higher variability of the clinical spectrum, as fetal complications[14,15], congenital heart defects[14], and isolated tubal torsion[16] were first described. Next to these specific items, the clinical presentation of these patients is mainly according to the phenotype described previously.

We here present 32 novel individuals with pathogenic variants in *USP7* and provide further clinical information about six previously described patients with a first report on intellectual functioning, growth parameters, and pregnancy complications. Finally, by creating a severity score of clinical phenotype, we provide an outline of genotype-phenotype correlations.

Subjects and Methods

This study is based on a 12-page questionnaire sent to all families listed in the USP7 registry. This registry was built in cooperation with the Foundation for USP7-related Diseases (www.USP7.org), enrolment was based on genotype. We included all individuals with confirmed genetic variants affecting the *USP7* gene and categorized patients based on type of mutations. Pathogenic variants, including cases from the literature, were standardized using Mutalzyer 3 (https://mutalyzer.nl), enabling us to compare all variants based on NM_003470.3. The questionnaire used within this study was designed with the Foundation for USP7-related Diseases to capture previously unrecognized symptoms. It was conceived to be filled out by the parents and always contained the option to select "unknown" if reporting was impossible. Growth centiles and z-scores were calculated using an online tool based on CDC standard values (https://www.pedz.de/en). Detailed clinical reports were requested, especially brain imaging and EEG reports. Thirty-eight families replied to the request and sent back at least the questionnaire and a genetic testing report, accompanied by a consent form.

Six of those patients had been previously reported by Fountain et al. in 2019[9]. We labeled the cases based on their chronological appearance in the literature and therefore report individuals #30 to #61 (*Supplemental table 1*).

If not stated otherwise, the frequency of the symptoms always describes the prevalence in all publicly accessible cases, including patients described by Hao et al., Fountain et al., Capra et al., Zampieri et al., Zheng et al., and the participants of this study[6,9,14,16,17].

A severity score was developed based on the most frequently occurring clinical features. Where available, the score considers the range of severity, e.g., one or two points based on the severity of the developmental delay. A scale of 0 to 24 points was assigned and normalized afterwards to avoid bias by data availability. The exact procedure next to the calculation of individual severity scores can be seen in the supplemental material (*supplemental methods, supplemental table 14*). Severity scores were calculated exclusively for participants of our study.

Differences between two groups for the severity index were evaluated using Student's t test. Whenever comparing more than one group for continuous variables (developmental milestones, growth parameters), a one-way ANOVA analysis was performed. One-sample t tests were performed in a z-normalized setting to assess deviation from the average population. All analyses were conducted using GraphPad (Version 9.5.1), and data for all patients were collected in IBM SPSS Statistics 29.

Results

We present 32 novel patients (16 M/16 W) with an average age of 9.97 years (2-20 years). All individuals harbor pathogenic variants affecting *USP7* (two whole-gene deletions, three partial gene deletions, one intragenic deletion, six truncating mutations, 15 missense mutations, and five splice-site mutations) (*Table 1*). The symptom reported most frequently is motor developmental delay, reflected by an overall delay in attainment of developmental milestones, followed by motor impairment, gait abnormalities, and muscular hypotonia. Furthermore, autism spectrum disorder (ASD), communication deficits, an abnormal pain threshold, gastrointestinal issues, and brain MRI anomalies are typical features presented by more than two-thirds of the cohort analyzed in this study. A summary of the most frequent symptoms is provided in *Table 2*, and a deeper analysis of all assessed symptoms subdivided by genotype can be found in the supplemental material (*Supplemental Tables 1-13*).

Growth parameters

Growth parameters from 39 patients indicate a trend towards increased height, weight, and BMI, with BMI achieving a statistically significant level (one sample t test; p_{BMI}= 0,0377). Among the entire cohort, the mean weight measures at the 62nd centile, the mean body height measures at the 61st centile, and the mean BMI (18.82) lies within the 61st centile (*Figure 1, Table 3*). For 34 total cases, we could analyze an age-adjusted BMI percentile. One case is below the 5th centile indicating underweight as defined by the CDC[18], 22 cases are in the average weight range, six fall in the overweight range, and five fulfill obesity criteria.

Therefore, 32 % of our entire cohort are overweight or obese. Although there is no general trend towards growth retardation, 13 % (6/48) of this patient cohort indicate short stature, defined as a body size at least two standard deviations below an age-adjusted standard population[19]. Furthermore, 14 of 43 (33 %) patients showed small hands, while 19 of 46 (41 %) showed small feet, in both cases defined as feet and hand length below the age-adjusted 25th percentile (for novel cases).

Pregnancy and birth

Contrary to the body measurements described above, patients demonstrated a trend towards reduced birth weight and body size. Average birth weight is at the 44th centile, and mean birth size at the 36th (*Figure 1, Table 3).* Neither sex nor genotype appear to influence growth parameters or birth body measurements (*Supplemental Figures 1-3*). Interestingly, we see both a subgroup being small for gestational age (birth weight below the 10th centile) and one being large for gestational age (birth weight above the 90th centile). The former criterion is met in 8 of 37 cases (22 %), the latter in six of 37 cases (16 %). Neonatal muscular hypotonia affected a majority of 25 out of 44 individuals (57 %). Head circumference measures at the gestational age-adjusted 47th centile and does not indicate altered head circumference at birth. A single patient (3%) manifested hydrocephalus as an infant. Twenty of 38 parents surveyed (53%) reported problems during pregnancy, which ranged from common pregnancy-related issues such as gestational diabetes to detected cardiac peculiarities or polyhydramnios. Decreased fetal movement was reported in seven of 44 cases (16 %). While preterm delivery occurred in eight of 40 cases (20 %), the mean gestational age was 37.77 weeks. 15 of 37 parents (41 %) reported complications after delivery and described those in a free-text answer, at which temperature instability was named most often (five times), followed by severe jaundice (four times) and respiratory distress (three times). Described congenital malformations met the criteria of having significant medical, social, or cosmetic consequences for the affected individual in 14 of 34 cases (41 %). After the first case of a HAFOUS patient with congenital anomalies was described by Capra et al. in 2019, we can now add 12 more individuals presenting anomalies of the cardiac system (four times), the motor system (3 times), dysmorphisms of the head (3 times), malformation of the oral cavity or pharynx (3 times), and one patient born with a duplex pelvicalyceal system in the right kidney.

Developmental milestones

According to WHO data, the first motor development milestone, "sitting without support," is reached after 6.0 months, while "hand-and-knees crawling" is reached after 8.5 months, and "walking alone" can be accomplished after 12.1 months of life in the general population[20]. Presenting a delay at every motor development milestone, the cohort described here reached free sitting on average after 11.7 months, crawling after 14.3 months, and free walking after 26.6 months (*Table 3*). Twenty-six of 46 patients reached unsupported sitting after more than 9.2 months, 14/27 patients reached crawling after more than 13.5 months, and 39/47 patients reached free walking after more than 17.6 months. Each of these mentioned time points represents the respective 99th centile in the general population.

Regarding speech developmental milestones, children are expected to speak their first word at 18 months and can build the first two-words sentences 24 months after birth[21]. The cohort described here spoke their first words on average after 21.1 months and built their first two-word sentence after 32.9 months (*Table 3*). In this study, the oldest patient being nonverbal was 14 years old and can also not safely walk without support (#43), while Fountain et al. have already described a 20-year-old patient as nonverbal.

Intellectual ability

Fifteen families provided intellectual testing reports, which featured a full-scale intelligence quotient in 10 cases and a description of severe ID in two cases (WISC or WPPSI testing procedures). The mean FSIQ for this cohort is 78.3 (*Table 3*) and falls within the range of borderline intellectual functioning. Nonetheless, two of 12 patients present an IQ below 35, which defines severe intellectual disability (ID). Four of 12 patients score between 50 and 69, indicating mild ID, two of 12 patients score between 70 and 85, indicating borderline intellectual functioning, and another four patients show normal intellectual functioning with an IQ above 85. The highest IQ measured in this cohort is 105. Two previously described patients scored in the range of moderate ID [15,16].

According to previously published data, an extensive chart and questionnaire review revealed signs of intellectual disability or (a history of) developmental delay in all cases.

Behavioral characteristics

Behavioral characteristics were stated to be a defining feature of HAFOUS and, therefore, also queried meticulously in this study. Testing for autism spectrum disorder was conducted in 15 cases, leading to a diagnosis in 10 cases (67 %). To overcome a selection bias, parents were also asked to state whether their child showed autistic features. Thirty-one parents reported positive testing or autistic behavioral features (72 %), while 12 neither tested positive nor showed behavioral features indicative of autism. ASD is more prevalent than initially expected in HAFOUS. Five of 21 parents reported an improvement of the autistic features over time, eight of 21 saw a worsening, and eight of 21 could not observe any change.

Nine of 42 reported an attention deficit hyperactivity disorder (ADHD) diagnosis (21 %), another 12 of 42 described ADHD-like behavioral traits, but lack of a formal diagnosis (29 %), and 21 of 42 did not observe any feature reminiscent of ADHD.

Previous publications indicated manifold behavioral traits, including aggressive behavior, temper tantrums, impulsivity, compulsivity, stubbornness, and manipulative behavior. Improving the objectivity of this assessment, we collected answers on a *Likert scale* for different behavioral traits, which would typically not be expected to appear often. Defined between 1 indicating "always" and five indicating "never", the scores ranged from 4.18 ("destructive in her/his room") to 2.46 ("stubbornness"). Next to the latter, "impulsivity", "overly social", and "physical contact seeking" scored values closer to always than never. Previously described features like "aggressiveness" or "manipulative behavior" scored 3.46 and 3.95, respectively (*supplemental figure 4*). Therefore, we can only partially confirm the previously described behavioral anomalies.

253 Furthermore, 10 of 29 parents reported general behavioral problems (34 %), 16 of 31 patients
254 showed obsessive-compulsive behavior (52 %), and only 9 of 52 parents observed skin picking
255 (17 %).
256
257 *Musculoskeletal phenotype*
258 One of the most frequent symptoms of HAFOUS is hypotonia, prevalent in 42 of 53 patients
259 (79 %). Hypotonia improved over time in the vast majority of 23 out of 30 cases (worsened in
260 two cases, no change in 5 cases). This is surprising, given that hypotonia at the time of
261 examination is more prevalent than neonatal hypotonia, indicating a numerical increase of
262 cases, although the individual courses may be ameliorating on average. Aside from low muscle
263 tone, other dysfunctions of the muscular system can be observed. Abnormal gait was reported
264 in 31 of 47 individuals (66 %), and 23 of 35 exhibit balance unsteadiness (66 %). Motor
265 dysfunction affects all categories and is indicated by fine motor delay/impairment (25/37, 68
266 %), gross motor delay/impairment (29/39, 74 %), as well as oral motor skills delay/impairment
267 (29/39, 76 %).
268 Less prevalent are scoliosis/kyphosis, which can be seen in 14 of 47 patients (30 %), and joint
269 contractures, reported by 11 of 45 affected families (24 %), most frequently located at the
270 lower extremity (6 cases).
271 Diverse dental issues were described by 20 of 36 parents (56 %), and the severity of the issues
272 ranges from severe malformations to cosmetic conspicuities. "Large front teeth" were
273 reported five times, while "deep palatal vault" and "supernumerary teeth" were reported
274 three times, respectively. Seventeen more issues were described no more than one time.
275
276 *Neurological/ ophthalmological features*
277 Eye anomalies were previously reported to affect a vast majority of HAFOUS patients. We can
278 confirm this for 28 of 53 patients in this cohort (53 %) and found farsightedness (10/34, 27 %)
279 to appear most frequently (*see supplemental tables*).
280 One of the queried items proposed by the foundation was an abnormal pain threshold, a
281 known symptom of PWS[22]. We saw a high threshold for pain at 19 of 34 (56 %) patients and a
282 low threshold for pain at another seven of 34 (21%) patients, indicating 76 % with a parent-
283 reported dysfunctional pain threshold.
284 Although delayed speech development was described for HAFOUS previously and is confirmed
285 here, speech abilities at a later stage have never been described. 24 of 37 (65 %) parents
286 reported limited communication skills, being reflected both by reduced expressive (26/38, 68
287 %) and receptive (23/36, 64 %) communication. Furthermore, parents were asked which
288 feature would be the most disabling symptom of their children and in 16 of all 38
289 questionnaires, parents reported speech problems as the most disabling feature, highlighting
290 the significance of this deficit for the affected individuals (cognitive impairment named nine
291 times, behavioral anomalies named eight times).
292 Hearing difficulties were reported in nine of 51 (18%) cases, and temperature instability was
293 reported in 14 of 34 (41 %) patients.

294 Fountain et al. extensively analyzed brain MRI reports in 2019, and we can mainly confirm
295 their findings based on the 13 new reports received. Combined with previously published
296 reports, brain MRIs exhibit anomalies of the ventricular system in 12 of 25 cases, signs of white
297 matter paucity/ small corpus callosum in 11/25 cases, simplified gyral patterns in 4/25 cases,
298 white matter hyperintensities in 3/25 cases, vermian atrophy in 3/25 cases, and hippocampal
299 anomaly as well as a thick corpus callosum one time respectively. Summarizing the reports,
300 23 of 34 (68 %) patients show any sign of abnormality described in their brain MRI report with
301 a wide variety of clinical significance as described above.
302
303 *Seizures and sleep*
304 Sleep disturbances were reported for 22 of 47 (47 %) patients and could partially explain the
305 frequent occurrence of fatigue (26/37, 70%) and a great need for rest (23/36, 64%). Sleep
306 apnea occurs in 10 of 34 (29 %) individuals.
307 Seizures were previously stated as a very prevalent and characteristic feature of HAFOUS. 23
308 of 57 (40 %) patients in the cohort described here were affected by seizures or have a history
309 of seizures; most effectively treated with anti-epileptic medications. The highest frequency of
310 seizures reported is 14 per year. Three of 32 (9 %) individuals had a febrile seizure. In most
311 cases, the reason for the seizures could not be clarified. Three of 19 (16 %) EEG reports we
312 received showed anomalies, in all three cases describing (probable) epileptic potential. Ten
313 parents provided information about the course of this symptom, and while four did not
314 observe any difference, six families confirmed an improvement concerning seizures over time.
315
316 *Gastrointestinal features*
317 This cohort's most frequent gastrointestinal issues are constipation or diarrhea, affecting 29
318 of 52 (56 %) patients. Incontinence inappropriate for the individual's age was reported by 15
319 of 38 (39 %) parents. Gastroesophageal reflux disease can be observed in 18 of 49 (37 %) cases,
320 and five of 35 (14 %) parents reported jaundice beyond the neonatal period. In four of 38 (10
321 %) cases, gastrointestinal issues were described as the most disabling symptom.
322
323 *Eating behavior*
324 Abnormal eating behavior is one of the key features of PWS and, therefore, also of great
325 interest in HAFOUS research. 30 out of 54 individuals (56 %) in the cohort here experienced
326 feeding difficulties during infancy, closely associated with 15 of 51 (29 %) patients having
327 difficulties gaining weight. Eating difficulties can be observed in 16 of 36 (44 %) cases. For the
328 first time, we describe 14 of 36 (39 %) HAFOUS patients presenting hyperphagia. While this
329 parental assessment lacks objectivity, further behavioral characteristics like mouthing
330 behavior (10/34, 29 %) and chewing of inedible objects (10/37, 27 %) support this finding.
331 Furthermore, 23 % (3/13) of the children showing hyperphagia are obese, while only 5 %
332 (1/20) fulfill this criterion in the non-hyperphagic group. Manifestation of hyperphagia began
333 three times in the neonatal period (first month of life), four times in infancy (second month
334 until the end of the second year), five times in early childhood (three until eight years), and
335 once later than that.

Further physical characteristics

We also asked for endocrinological and respiratory dysfunction but could not identify any features of high prevalence.

Hypothyroidism (1/21, 5 %), adrenal insufficiency (1/21, 5 %), and growth (GH) deficiency (2/24, 8 %) were reported in only few patients, while hypogonadism was observed in 11 of 47 patients (23 %). We also included 4 of 16 boys with cryptorchidism/ micropenis.

Only a few patients depended on respiratory assistance in the form of intubation (2/35, 6 %) or mechanical ventilation (3/35, 9 %). In 2 of 3 cases, chart review revealed that ventilation was necessary immediately postnatally, while the context could not be outlined for one further case. Asthma was prevalent in 8 of 36 (22 %) patients.

Eczema was described by 12 of 34 (35 %) parents.

Genotype-phenotype association

The cause of clinical heterogeneity in *USP7*-related disorder is not very well understood. Aiming to overcome this issue, a the severity score was developed as described before (methods, supplemental methods). Anderson-Darling test (p=0.4699), Shapiro-Wilk test (p=0.3424), and Kolmogorov-Smirnov test (p>0.1) were passed. Therefore, normal distribution can be assumed (*supplemental figure 5A*). The mean severity score is 0.4937 (SD: 0.1561) for the 38 values we generated.

To better understand influencing factors on the severity, we compared both sexes and found no difference (M: 0.49 SD 0.14, n:16; W: 0.50 SD 0.17, n:22) (*figure 2A).* Furthermore, age and type of the underlying genotype do not influence severity significantly (DEL: 0.47 SD 0.13, NON: 0.41 SD 0.12, MISS: 0.53 SD 0.18, SPLIC: 0.49 SD 0.07) (*figure 2B, supplemental figure 5B*). Due to the heterogeneity of severity within the group harboring missense mutations, a correlation of exact position of the mutation and severity was investigated Missense mutations were grouped based on functionally relevant protein regions. A mean value of 0.64 (n: 10) was found for the catalytic domain, 0.48 (n: 2) for the TRAF domain, and 0.41 (n: 8) for the UBL-like domain, reflecting a significantly increased severity score for mutations affecting the catalytic domain of USP7 (figure 2C, p = 0.0041).

Based on these results, we hypothesize that missense variants within the catalytic domain of the protein are associated with a more severe clinical phenotype compared to variants in the other parts of the protein.

Discussion

HAFOUS is a neurodevelopmental disorder leading to a variable clinical spectrum in terms of occurrence and severity of symptoms. Speech and motor delay are most prevalent. Patients typically present with communication deficits, muscular hypotonia, motor issues, abnormal threshold for pain, and autism spectrum disorder. Complications during birth and congenital anomalies are frequently present. Further symptoms such as seizures, hyperphagia, or scoliosis only affect a subset of individuals. As previously proposed, this disorder can be considered part of a disease family with SYS and PWS[23], showing a wide overlap of symptoms

between these disorders and a hypothesized shared path of pathophysiology via the MUST complex[10]. Developmental delay, muscular hypotonia, reduced birth weight, and infant feeding difficulties are shared features among these disorders[8,11].

Furthermore, endocrine dysfunction, also described as hypothalamic insufficiency, is a crucial feature of SYS and PWS, but could not be seen frequently in our cohort[24,25]. ASD is much more prevalent in HAFOUS and SYS (72 % and 78 %) compared to PWS (27 %)[11,26]. SYS, with its unique prevalence of joint contractures and respiratory dysfunctions accompanied by the most severe manifestation of developmental delay, intellectual disability, and increased mortality, can be considered the most severe disorder within this disease family[11]. The causative factors need to be further investigated, but a neomorphic function of the truncated MAGEL2 protein or a suppression of leaky expression from the maternal allele at SYS was previously hypothesized to contribute to the alteration of manifestation between these disorders[10]. HAFOUS positions itself as the least severe manifestation within this disease family due to milder developmental delay, higher intellectual functioning, and mostly an absence of endocrine dysfunctions (see[11,27,28]). Considering the MUST pathway as one of the driving factors of these diseases, it is noteworthy to mention that pathogenic variants in *USP7* were reported only heterozygous, suggesting the presence of wild-type and variant USP7 proteins, while MAGEL2 mutations associated with PWS and SYS are functionally hemizygous, suggesting the complete absence of wild-type MAGEL2. Therefore, it can be presumed that mutations underlying SYS or PWS have a greater impact on the functionality of the MUST complex than mutations causing HAFOUS. Nevertheless, the variability of symptoms is intriguing, and some patients face a much more severe phenotype than others. Although we provide data indicating the most severe phenotypes in patients with missense variants within the catalytic domain, predicting the severity of phenotypes based on individual mutations remains challenging.

This work sheds light on new, previously undescribed features of HAFOUS. Most remarkably, we found an abnormal threshold for pain affecting 76 % of the cohort. Furthermore, we describe some individuals presenting hyperphagia and potentially associated obesity. Complications during pregnancy and congenital anomalies of varying severity had not been reported previously. In addition to describing symptoms for the first time, we provide more profound data for all previously described symptoms and observe a higher prevalence of ASD than indicated by previous studies. Some features like seizures and particularly aggressive and impulsive behavior are not as prevalent as initially hypothesized. We recommend analyzing larger cohorts even in the initial phase of investigating a novel disease to ensure a reliable foundation of data. Our approach to include the disease community when creating the questionnaire, appears helpful for gathering data on previously undescribed features.

TRIM27 is another component of the MUST-complex and was not previously described in case reports or systematic patient cohort analyses of neurodevelopmental disorders. This is surprising as other proteins of this pathway can be assigned to various neurodevelopmental conditions[10]. We currently aim to identify individuals carrying *TRIM27* mutations to provide a systematic analysis.

Interestingly, a recent paper implicates all the variable functions of USP7, but especially contribution of USP7 to epigenetic transcriptional regulation, in the search for an etiology of HAFOUS[29]. This seems reasonable to us as this group revealed that USP7 is highly associated with histone ubiquitination on a transcriptional and posttranslational level as a silencer or stabilizing partner for relevant factors of the PRC1 complex and therefore contributes to the expression of several neurodevelopmental factors like AUTS2[29]. Establishing animal models of this disorder could help understand the exact mechanism of pathophysiology and the cellular pathways contributing to the phenotype. Remarkably, an overexpression mouse model of *Usp7* presented altered dendritic arborization, neuronal migration, a behavioral phenotype, and altered pain threshold, which is partially reminiscent of the phenotype observed in our cohort suggesting dosage-sensitivity of Usp7 during neurodevelopment[30].

This study is subject to some limitations. The symptoms were recorded in a questionnaire by interviewing the parents and are thus primarily subjective. Whenever possible, clinical charts and records were assessed to ensure objectivity.

A phenotyping study of individuals at the University Hospital of Heidelberg is currently being conducted to overcome this issue. By analyzing 32 novel and six previously described patients, this study helps understand the clinical spectrum of HAFOUS, reveals undescribed symptoms, and provides a first approach to a genotype-phenotype correlation. With this, we intend to contribute to a more reliable and sound genetic consulting and prediction of phenotype for affected individuals and families.

461 **5 References**

462

463 1. Valles GJ, Bezsonova I, Woodgate R, Ashton NW. USP7 Is a Master Regulator of
464 Genome Stability. *Front Cell Dev Biol*. 2020;8:717. doi:10.3389/fcell.2020.00717
465 2. Bhattacharya S, Chakraborty D, Basu M, Ghosh MK. Emerging insights into HAUSP
466 (USP7) in physiology, cancer and other diseases. *Signal Transduct Target Ther*. 2018;3:17.
467 doi:10.1038/s41392-018-0012-y
468 3. Pozhidaeva A, Bezsonova I. USP7: Structure, substrate specificity, and inhibition. *DNA*
469 *Repair (Amst)*. Apr 2019;76:30-39. doi:10.1016/j.dnarep.2019.02.005
470 4. Kim RQ, Sixma TK. Regulation of USP7: A High Incidence of E3 Complexes. *J Mol Biol*.
471 Nov 10 2017;429(22):3395-3408. doi:10.1016/j.jmb.2017.05.028
472 5. Hao YH, Doyle JM, Ramanathan S, et al. Regulation of WASH-dependent actin
473 polymerization and protein trafficking by ubiquitination. *Cell*. Feb 28 2013;152(5):1051-64.
474 doi:10.1016/j.cell.2013.01.051
475 6. Hao YH, Fountain MD, Jr., Fon Tacer K, et al. USP7 Acts as a Molecular Rheostat to
476 Promote WASH-Dependent Endosomal Protein Recycling and Is Mutated in a Human
477 Neurodevelopmental Disorder. *Mol Cell*. Sep 17 2015;59(6):956-69.
478 doi:10.1016/j.molcel.2015.07.033
479 7. Schaaf CP, Gonzalez-Garay ML, Xia F, et al. Truncating mutations of MAGEL2 cause
480 Prader-Willi phenotypes and autism. *Nat Genet*. Nov 2013;45(11):1405-8.
481 doi:10.1038/ng.2776
482 8. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. *Genet Med*. Jan
483 2012;14(1):10-26. doi:10.1038/gim.0b013e31822bead0
484 9. Fountain MD, Oleson DS, Rech ME, et al. Pathogenic variants in USP7 cause a
485 neurodevelopmental disorder with speech delays, altered behavior, and neurologic
486 anomalies. *Genet Med*. Aug 2019;21(8):1797-1807. doi:10.1038/s41436-019-0433-1
487 10. Fountain MD, Schaaf CP. Prader-Willi Syndrome and Schaaf-Yang Syndrome:
488 Neurodevelopmental Diseases Intersecting at the MAGEL2 Gene. *Diseases*. Jan 13
489 2016;4(1)doi:10.3390/diseases4010002
490 11. McCarthy J, Lupo PJ, Kovar E, et al. Schaaf-Yang syndrome overview: Report of 78
491 individuals. *Am J Med Genet A*. Dec 2018;176(12):2564-2574. doi:10.1002/ajmg.a.40650
492 12. Fountain MD, Aten E, Cho MT, et al. The phenotypic spectrum of Schaaf-Yang
493 syndrome: 18 new affected individuals from 14 families. *Genet Med*. Jan 2017;19(1):45-52.
494 doi:10.1038/gim.2016.53
495 13. Castilla-Vallmanya L, Centeno-Pla M, Serrano M, et al. Advancing in Schaaf-Yang
496 syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2. *J*
497 *Med Genet*. Sep 7 2022;doi:10.1136/jmg-2022-108690
498 14. Capra AP, Agolini E, La Rosa MA, Novelli A, Briuglia S. Correspondence on "Pathogenic
499 variants in USP7 cause a neurodevelopmental disorder with speech delays, altered behavior,
500 and neurologic anomalies" by Fountain et al. *Genet Med*. Feb 2021;23(2):421-422.
501 doi:10.1038/s41436-020-00978-x
502 15. Priolo M, Mancini C, Pizzi S, et al. Complex Presentation of Hao-Fountain Syndrome
503 Solved by Exome Sequencing Highlighting Co-Occurring Genomic Variants. *Genes (Basel)*.
504 May 16 2022;13(5)doi:10.3390/genes13050889
505 16. Zampieri N, Pulvirenti R, Pedrazzoli E, Camoglio FS. Hao-Fountain syndrome and
506 genital disorders: report of a new possible association. *Ital J Pediatr*. Oct 22 2022;48(1):182.
507 doi:10.1186/s13052-022-01367-7

17. Zheng H, Mei S, Li F, et al. Expansion of the mutation spectrum and phenotype of USP7-related neurodevelopmental disorder. *Front Mol Neurosci*. 2022;15:970649. doi:10.3389/fnmol.2022.970649

18. Skinner AC, Perrin EM, Skelton JA. Prevalence of obesity and severe obesity in US children, 1999-2014. *Obesity (Silver Spring)*. May 2016;24(5):1116-23. doi:10.1002/oby.21497

19. Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P, International Small for Gestational Age Advisory B. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001. *Pediatrics*. Jun 2003;111(6 Pt 1):1253-61. doi:10.1542/peds.111.6.1253

20. Group WHOMGRS. WHO Motor Development Study: windows of achievement for six gross motor development milestones. *Acta Paediatr Suppl*. Apr 2006;450:86-95. doi:10.1111/j.1651-2227.2006.tb02379.x

21. Dosman CF, Andrews D, Goulden KJ. Evidence-based milestone ages as a framework for developmental surveillance. *Paediatr Child Health*. Dec 2012;17(10):561-8. doi:10.1093/pch/17.10.561

22. Butler MG, Miller JL, Forster JL. Prader-Willi Syndrome - Clinical Genetics, Diagnosis and Treatment Approaches: An Update. *Curr Pediatr Rev*. 2019;15(4):207-244. doi:10.2174/1573396315666190716120925

23. Marbach F, Schaaf CP. Response to Briuglia et al. *Genet Med*. Feb 2021;23(2):423-424. doi:10.1038/s41436-020-00977-y

24. McCarthy JM, McCann-Crosby BM, Rech ME, et al. Hormonal, metabolic and skeletal phenotype of Schaaf-Yang syndrome: a comparison to Prader-Willi syndrome. *J Med Genet*. May 2018;55(5):307-315. doi:10.1136/jmedgenet-2017-105024

25. Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. *J Endocrinol Invest*. Dec 2015;38(12):1249-63. doi:10.1007/s40618-015-0312-9

26. Bennett JA, Germani T, Haqq AM, Zwaigenbaum L. Autism spectrum disorder in Prader-Willi syndrome: A systematic review. *Am J Med Genet A*. Dec 2015;167A(12):2936-44. doi:10.1002/ajmg.a.37286

27. Thomason MM, McCarthy J, Goin-Kochel RP, Dowell LR, Schaaf CP, Berry LN. Neurocognitive and Neurobehavioral Phenotype of Youth with Schaaf-Yang Syndrome. *J Autism Dev Disord*. Jul 2020;50(7):2491-2500. doi:10.1007/s10803-018-3775-7

28. Curfs LM, Fryns JP. Prader-Willi syndrome: a review with special attention to the cognitive and behavioral profile. *Birth Defects Orig Artic Ser*. 1992;28(1):99-104.

29. Sijm A, Atlasi Y, van der Knaap JA, et al. USP7 regulates the ncPRC1 Polycomb axis to stimulate genomic H2AK119ub1 deposition uncoupled from H3K27me3. *Sci Adv*. Nov 4 2022;8(44):eabq7598. doi:10.1126/sciadv.abq7598

30. Qiao H, Tian Y, Huo Y, Man HY. Role of the DUB enzyme USP7 in dendritic arborization, neuronal migration, and autistic-like behaviors in mice. *iScience*. Jul 15 2022;25(7):104595. doi:10.1016/j.isci.2022.104595

7 Legends

Figure 1: Body measurements of patients with Hao-Fountain Syndrome; one sample t-test performed for a mean value of 50
A: BMI subdivided by normal weight, overweight, obesity; B: Current measurement percentiles; C: Birth measurement percentiles

Figure 2: Assessment of severity score values in variable subgroups; Student's t-test and one-way ANOVA
A: Severity score plotted for sex.; B: Severity score for each type of mutation.; C: Severity score of missense mutations grouped by localization (Catalytic domain vs. TRAF- and UBL-domain).

Table 1 Novel cases with pathogenic USP7 variants

Table 2 Summary of published and novel cases with pathogenic USP7 variants

Table 3 Developmental/ speech milestones, growth parameters, and IQ of patients with Hao-Fountain Syndrome

Supplemental figure 1: Body measurements compared by sex
A: BMI values (Student's t-test).; B: Current body measurement percentiles; C: Birth body measurement percentiles

Supplemental figure 2: Current body measurements compared by genotype
A: BMI values (One-way ANOVA); B: Current body length percentile (One-way ANOVA); C: Current body weight percentile (One-way ANOVA); D: BMI percentile (One-way ANOVA)

Supplemental figure 3: Birth body measurements compared by sex and genotype
A: Birth body weight percentiles (One-way ANOVA); B: Birth head circumference percentiles (One-way ANOVA); C: Birth body length percentiles (One-way ANOVA); D: Birth measurements compared by sex

Supplemental figure 4: Behavioral traits of Hao-Fountain syndrome patients
Several behavioral traits and parental-reported frequency of occurrence ranging from 5 (Always) to 1 (Never) (n: 36).

Supplemental Figure 5: Severity score QQ plot and assessment for different subgroups

A: QQ plot proofing normal distribution of severity scores within our cohort; B: Severity score plotted against age of individuals (slope: 0,0004920) indicating no impact of age on severity; C: Severity score of patients with a truncating mutation plotted for the location of the predicted location of the truncation; D: Severity score of patients with a missense mutation plotted for the location of the predicted location of the truncation (Tukey's multiple comparison test following one-way ANOVA; CD vs. UBL: adjusted p-value = 0.0131)

Supplemental table 1 – Molecular phenotype: Comprehensive molecular phenotype information on known patients with HAFOUS, including variant coordinates, inheritance, and mutational group allocation, all based on NM_003470.3. Novel cases identified as individuals #30-#61.

Supplemental table 2 – Behavioral and cognitive profile: Behavioral phenotypical aspects of all known individuals with HAFOUS, also containing information about cognition (sorted by mutation type).

Supplemental table 3 – Motor + speech development: Milestones in motor and speech development for HAFOUS patients, categorized by mutation type.

Supplemental table 4 – Musculoskeletal phenotype: Musculoskeletal phenotypic features observed in HAFOUS patients, categorized by mutation type.

Supplemental table 5 – Neurological phenotype: Neurological manifestations in HAFOUS patients, sorted by mutation type.

Supplemental table 6 – Endocrine phenotype: Detailed endocrine phenotype of HAFOUS patients, sorted by mutation type.

Supplemental table 7 – Respiratory phenotype: Respiratory phenotype in HAFOUS patients, categorized by mutation type.

Supplemental table 8 – Sleep + seizures + EEG: Sleep patterns, EEG study results, and seizure occurrences in HAFOUS patients, sorted by mutation type.

Supplemental table 9 – Eating behavior: Parental-reported eating behavior of all known individuals with HAFOUS, sorted by mutation type.

Supplemental table 10 – Gastrointestinal phenotype: Gastrointestinal phenotypes in HAFOUS patients, categorized by mutation type.

Supplemental table 11 – Body measurements: Comprehensive body measurements of HAFOUS patients, sorted by mutation type.

Supplemental table 12 – Birth and neonatal period: Phenotypic aspects of the birth and neonatal period in HAFOUS patients, categorized by mutation type.

Supplemental table 13 – More phenotypical aspects: Further phenotypical aspects of HAFOUS patients, sorted by type of mutation. Also containing parental-reported symptoms not being listed in our questionnaire and parental-identified aspects being “most disabling” and “the most striking capability”.

Supplemental table 14 – Severity score: Calculation of severity scores for HAFOUS patients meeting missense or truncating mutation criteria within our cohort. Includes points per category, cumulative points, maximum achievable points, and severity scores per individual.

Figures



Figure 1: Body measurements of patients with Hao-Fountain Syndrome; one sample t-test performed for a mean value of 50

A: BMI subdivided by normal weight, overweight, obesity; B: Current measurement percentiles; C: Birth measurement percentiles



Figure 2: Assessment of severity score values in variable subgroups; Student's t-test and one-way ANOVA

A: Severity score plotted for sex.; B: Severity score for each type of mutation.; C: Severity score of missense mutations grouped by localization (Catalytic domain vs. TRAF- and UBL-domain).